Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323. No abstract available.

PMID:
28248313
2.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148. Epub 2016 May 23. Erratum in: Leukemia. 2017 Mar;31(3):775.

3.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, McQuitty M, Stalbovskaya V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al-Ali HK.

Exp Hematol Oncol. 2015 Sep 15;4:26. doi: 10.1186/s40164-015-0021-2. eCollection 2015.

4.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H; COMFORT-II investigators.

Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30. Erratum in: Blood. 2016 Dec 22;128(25):3013.

5.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C.

Haematologica. 2014 Feb;99(2):292-8. doi: 10.3324/haematol.2013.087650. Epub 2013 Aug 2.

6.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G.

N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.

7.

Close encounters with the legal aspects of private practice.

McQuitty M.

Beginnings. 2006 Spring;26(2):14-5. No abstract available.

PMID:
16625882
8.

Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.

Franco RJ, Goldflus S, McQuitty M, Oigman W; Valsartan/HCTZ Combination Therapy in Brazil Study Group.

Blood Press Suppl. 2003 Dec;2:41-7.

PMID:
14761076
9.

Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid.

Conte JE Jr, Golden JA, McQuitty M, Kipps J, Duncan S, McKenna E, Zurlinden E.

Antimicrob Agents Chemother. 2002 Aug;46(8):2358-64. Erratum in: Antimicrob Agents Chemother. 2002 Sep;46(9):3112..

10.

Undiagnosed and unreported AIDS deaths: results from the San Francisco Medical Examiner.

Scheer S, McQuitty M, Denning P, Hormel L, Stephens B, Katz M, Schwarcz S.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):467-71.

PMID:
11511824
11.

Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations.

Conte JE Jr, Golden JA, McQuitty M, Kipps J, Lin ET, Zurlinden E.

Antimicrob Agents Chemother. 2000 May;44(5):1337-41.

12.

Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.

Conte JE Jr, Golden JA, McQuitty M, Kipps J, Lin ET, Zurlinden E.

Antimicrob Agents Chemother. 2000 Apr;44(4):985-90.

13.

Home collection versus publicly funded HIV testing in San Francisco: who tests where?

McQuitty M, McFarland W, Kellogg TA, White E, Katz MH.

J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):417-22.

PMID:
10458624
14.

Postoperative Serratia marcescens wound infections traced to an out-of-hospital source.

Passaro DJ, Waring L, Armstrong R, Bolding F, Bouvier B, Rosenberg J, Reingold AW, McQuitty M, Philpott SM, Jarvis WR, Werner SB, Tompkins LS, Vugia DJ.

J Infect Dis. 1997 Apr;175(4):992-5.

PMID:
9086167
15.

Latent silicosis.

McQUITTY M, CUDDIHY B, MacINTOSH CA, ADAMS GT.

Can Med Assoc J. 1950 Jul;63(1):69-70. No abstract available.

16.

Supplemental Content

Loading ...
Support Center